A Mini-Sentinel assessment by the US Food and Drug Administration (FDA) has confirmed the positive safety and efficacy profile of Janssen Pharmaceutical’s Xarelto (rivaroxaban) determined in the Phase III ROCKET AF clinical trials.

The FDA report indicated lower ischemic stroke risk with Xarelto when compared to warfarin, which lasted over the three-year assessment.

Xarelto is a prescription medicine to minimise the risk of stroke and blood clots in atrial fibrillation patients, as well as to treat deep vein thrombosis (DVT) and pulmonary embolism (PE).

The Mini-Sentinel, which is created to support existing safety surveillance methods, analysed Xarelto’s safety in non-valvular atrial fibrillation (AF) patients who used the drug or warfarin from November 2011 to April 2015.

“These FDA results yet again confirm the positive benefit-risk profile of Xarelto across a wide range of patients.”

Methodologies such as CD-9-CM code evaluation, gastrointestinal (GI) bleeding rates, ischemic stroke and intracranial haemorrhage were used to evaluate the safety of the products.

The study did not reveal any new safety concerns with the use of rivaroxaban.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Janssen Pharmaceuticals Medical Affairs vice-president Paul Burton said: “We’re pleased to see the Sentinel Initiative in action and that FDA’s findings are consistent with results from other independent real-world and post-marketing studies.

“These FDA results yet again confirm the positive benefit-risk profile of Xarelto across a wide range of patients.”